MLTX · MoonLake Immunotherapeutics
$15.75
-0.99 (-5.91%)
At close · Aug 20
Market Cap
$1.42B
Shares
85.11M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$227.32M
-91.1%
FY2025
Diluted EPS
-$3.53
-86.8%
FY2025
Operating Cash Flow
-$196.01M
-68.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $221.38M | $202.86M | $112.77M | $31.8M | $42.05M | — | — | |
| $46.96M | $41.97M | $30.32M | $22.32M | $23.01M | $4.57M | — | |
| — | $2.62M | $1.39M | $370K | $164.78K | — | — | |
| $268.34M | $244.83M | $143.09M | $54.12M | $65.06M | — | — | |
| -$268.34M | -$244.83M | -$143.09M | -$54.12M | -$65.06M | -$4.57M | -$105.76K | |
| $10.09M | $7.25M | $0 | $0 | — | — | — | |
| $18.31K | — | — | — | — | $27.69K | $14.92K | |
| $3.19M | — | — | — | $591.73K | $27.69K | — | |
| — | -$229.71M | -$120.96M | -$43.99M | -$64.47M | — | — | |
| $1.08M | $611K | $282K | $94K | $36.37K | — | — | |
| -$263.05M | -$227.32M | -$118.94M | -$36.01M | -$49.97M | -$4.54M | -$90.84K | |
| -$1.56M | -$3M | -$2.31M | -$8.07M | -$14.53M | -$4.54M | — | |
| -$263.57M | -$231.73M | -$116.38M | -$34.51M | -$49.44M | — | — | |
| USD/shares | — | -$3.53 | -$1.89 | -$0.73 | -$1.70 | — | — |
| USD/shares | — | -$3.53 | -$1.89 | -$0.73 | -$1.70 | — | — |
| shares | — | 64.46M | 62.87M | 49.12M | 29.36M | 11.93M | — |
| shares | — | 64.46M | 62.87M | 49.12M | 29.36M | 360M | — |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2024: $50 in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 7.34×
EV/EBIT
—
Peer median 26.68×
P/E (TTM)
—
Peer median 17.90×
Peer medians compare against the 290 similar-size Biotechnology companies (of 546 listed).
Key facts
CIK
1821586
CUSIP
61559X104
13F (30d)
173 filings
167 filers
Visit website
Investor relations